GILD Gilead Sciences Inc

Price (delayed)

$69.07

Market cap

$86.64B

P/E Ratio

11.73

Dividend/share

$2.84

EPS

$5.89

Enterprise value

$109.96B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
GILD's P/E is 95% below its last 4 quarters average of 217.4 and 83% below its 5-year quarterly average of 67.7
The company's net income rose by 43% QoQ
The quick ratio has plunged by 66% YoY and by 3.8% from the previous quarter

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$86.64B
Enterprise value
$109.96B
Valuations
Price to earnings (P/E)
11.73
Price to book (P/B)
4.03
Price to sales (P/S)
3.16
EV/EBIT
10.59
EV/EBITDA
8.92
EV/Sales
4
Earnings
Revenue
$27.48B
EBIT
$10.39B
EBITDA
$12.33B
Free cash flow
$9.49B
Per share
EPS
$5.89
Free cash flow per share
$7.56
Book value per share
$17.12
Revenue per share
$21.88
TBVPS
$19.8
Balance sheet
Total assets
$67.1B
Total liabilities
$45.63B
Debt
$27.69B
Equity
$21.47B
Working capital
$3.75B
Liquidity
Debt to equity
1.29
Current ratio
1.37
Quick ratio
1.01
Net debt/EBITDA
1.89
Margins
EBITDA margin
44.9%
Gross margin
80.5%
Net margin
26.9%
Operating margin
42.3%
Efficiency
Return on assets
10.9%
Return on equity
37.8%
Return on invested capital
25.9%
Return on capital employed
18.3%
Return on sales
37.8%
Dividend
Dividend yield
4.11%
DPS
$2.84
Payout ratio
48.2%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
-1.93%
1 week
-4.4%
1 month
-4.35%
1 year
2.98%
YTD
-4.88%
QTD
-4.88%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.48B
Gross profit
$22.11B
Operating income
$11.63B
Net income
$7.39B
Gross margin
80.5%
Net margin
26.9%
The company's net income rose by 43% QoQ
Gilead Sciences's net margin has increased by 39% QoQ
GILD's gross profit is up by 21% YoY and by 3.6% QoQ
The operating income has grown by 19% since the previous quarter

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
11.73
P/B
4.03
P/S
3.16
EV/EBIT
10.59
EV/EBITDA
8.92
EV/Sales
4
GILD's P/E is 95% below its last 4 quarters average of 217.4 and 83% below its 5-year quarterly average of 67.7
GILD's EPS is up by 43% since the previous quarter
Gilead Sciences's equity has increased by 23% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 4% less than its 5-year quarterly average of 4.2 and 4% less than its last 4 quarters average of 4.2
GILD's revenue is up by 19% year-on-year and by 3.2% since the previous quarter
GILD's price to sales (P/S) is 12% less than its 5-year quarterly average of 3.6

Efficiency

How efficient is Gilead Sciences business performance
Gilead Sciences's ROIC has increased by 45% from the previous quarter
GILD's return on assets is up by 40% since the previous quarter
The company's return on equity rose by 36% QoQ
GILD's return on sales is up by 30% since the previous quarter

Dividends

What is GILD's dividend history
DPS
$2.84
Dividend yield
4.11%
Payout ratio
48.2%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 47% higher than its total liabilities
The quick ratio has plunged by 66% YoY and by 3.8% from the previous quarter
Gilead Sciences's current ratio has shrunk by 58% YoY
Gilead Sciences's debt is 29% higher than its equity
Gilead Sciences's equity has increased by 23% YoY and by 9% from the previous quarter
The company's debt to equity fell by 23% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.